FindTrial
Sign In

DM199

DRUG5 trials

Sponsors

DiaMedica Therapeutics Inc, Stellenbosch University

Conditions

Chronic Kidney DiseaseChronic Kidney Disease, Stage 3 (Moderate)Chronic Kidney Disease, Stage 4 (Severe)DiabetesDiabetes Type 2Kidney DiseasesPre-EclampsiaPregnancy and Childbirth

Phase 1

A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients
CompletedNCT01845064
DiaMedica Therapeutics IncDiabetes Type 2
Start: 2013-04-30End: 2014-11-30Updated: 2014-12-19
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
CompletedNCT03795389
DiaMedica Therapeutics IncChronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe) +1
Start: 2019-02-12End: 2019-07-21Updated: 2021-09-13
DM199 for Pregnancy Complications
RecruitingPACTR202404895013782
Stellenbosch UniversityPregnancy and Childbirth
Start: 2024-11-01Target: 120Updated: 2026-08-03

Phase 2

Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
CompletedNCT04123613
DiaMedica Therapeutics IncKidney Diseases
Start: 2019-12-17End: 2022-03-16Updated: 2022-03-31

Unknown Phase

DM199 for Pregnancy Complications
WithdrawnNCT06875141
DiaMedica Therapeutics IncPre-Eclampsia
Start: 2025-05-31End: 2025-05-31Updated: 2025-06-04

Related Papers

Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial.
2025-12-17